Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.71 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.71 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13219574 | 0.86 | MAPT (1.00) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL7820388 | 0.84 | KMT2A (0.64) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL16179844 | 0.81 | SIRT6 (1.00) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL16179842 | 0.79 | KMT2A (0.83) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL16179518 | 0.79 | SIRT6 (1.00) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL6635707 | 0.77 | SMN1; SMN2 (0.69) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13870855 | 0.77 | MEN1 (0.72) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13219539 | 0.77 | KCNMA1 (0.79) | MAPTKMT2AMEN1GAARAB9A | |
| SCHEMBL13219577 | 0.77 | PTPN2 (0.79) | MAPTKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL16179714 | 0.77 | MEN1 (1.00) | MAPTKMT2AMEN1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | MAPT 2862/4885KMT2A 3872/4885MEN1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.